SCHEMBL2279768

SCHEMBL2279768

COC(=O)CNC(=O)c1ccc(C=CC(=O)c2c(OC)cc(C)n(C)c2=O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 7/20 0.45
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42
MKNK2 Q9HBH9 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
ATM Q13315 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
KDM4E B2RXH2 1/20 0.41
TSHR P16473 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
APP P05067 2/20 0.41
NFKB1 P19838 1/20 0.40
DPP4 P27487 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2279763 1.00 ABCG2 (0.45) ABCG2CYP1A2CYP2C19MKNK2TDP1
SCHEMBL2281403 0.92 ABCG2 (0.45) ABCG2MKNK2TDP1MEN1KMT2A
SCHEMBL2281395 0.92 ABCG2 (0.45) ABCG2MKNK2TDP1MEN1KMT2A
SCHEMBL2278778 0.90 MAPK1 (0.42) ABCG2MEN1KMT2AMAPTNPSR1
SCHEMBL2278780 0.90 MAPK1 (0.42) ABCG2MEN1KMT2AMAPTNPSR1
SCHEMBL2277293 0.89 APP (0.43) ABCG2CYP1A2CYP2C19MKNK2MEN1
SCHEMBL2277289 0.89 APP (0.43) ABCG2CYP1A2CYP2C19MKNK2MEN1
SCHEMBL2280423 0.82 SMN1; SMN2 (0.42) ABCG2MEN1KMT2AMAPTATM
SCHEMBL2280425 0.82 SMN1; SMN2 (0.42) ABCG2MEN1KMT2AMAPTATM
SCHEMBL2281269 0.79 P4HB (0.41) ABCG2CYP2C19MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 ABCG2 4878/4885CYP1A2 2505/4885CYP2C19 4627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.